Atai extends cash runway into 2027 despite $39M fourth-quarter loss

https://s43720.pcdn.co/wp-content/uploads/2024/11/money-stock-chart-technology.jpg

Atai Life Sciences (Nasdaq: ATAI) posted a $39 million net loss for the fourth quarter of 2024 but announced Monday that it boosted its financial position with a recent equity offering that extends its operational runway into 2027.

The clinical-stage company, which mainly focuses on developing psychedelic-based treatments for mental health…

Please login to read all 428 words.

Leave a Reply

Your email address will not be published. Required fields are marked *